The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Nyxoah SA (developing a hypoglossal nerve stimulation therapy for obstructive sleep apnea) raised €15mm ($17.1mm) in its third financing round, which was led by Cochlear Ltd. (adds a board member) and returning shareholders. The company will use the funds to commence post-CE Mark European market development activities and work towards IDE with the FDA.

+ Show All | – Hide All


Click a figure for comparable deals.

Potential Deal Value $17.10mm
Transactions 1 of 1 (11/2018)
Round # 3
Funding Stage Additional Round
Equity $17.10mm
Total Line Value $17.10mm
Gross Proceeds $17.10mm
Investors Cochlear Ltd.

Deal Information

Click a keyword for comparable deals.

Deal Industry Medical Devices
Implantable Devices
Deal Status Final
Deal Type Financing
Private Placement

Company Information

Click a keyword for comparable companies.

Nyxoah SA
View Company Profile | View Company Deals
Company Location Worldwide
Western Europe
Industry Medical Devices
Implantable Devices
Ownership Private
Therapeutic Area(s) of Focus Respiratory, Pulmonary